Boothbay Fund Management’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-66,276
| Closed | -$272K | – | 2907 |
|
|
2022
Q1 | $272K | Sell |
66,276
-208,749
| -76% | -$757K | 0.01% | 1677 |
|
|
2021
Q4 | $982K | Buy |
275,025
+101,315
| +58% | +$354K | 0.02% | 760 |
|
|
2021
Q3 | $632K | Buy |
173,710
+93,288
| +116% | +$377K | 0.02% | 980 |
|
|
2021
Q2 | $351K | Buy |
80,422
+45,983
| +134% | +$187K | 0.01% | 1190 |
|
|
2021
Q1 | $142K | Sell |
34,439
-23,475
| -41% | -$102K | 0.01% | 1435 |
|
|
2020
Q4 | $231K | Buy |
57,914
+36,168
| +166% | +$117K | 0.01% | 1053 |
|
|
2020
Q3 | $59K | Buy |
21,746
+10,504
| +93% | +$29.1K | ﹤0.01% | 998 |
|
|
2020
Q2 | $31K | Sell |
11,242
-26,756
| -70% | -$74.7K | ﹤0.01% | 929 |
|
|
2020
Q1 | $90K | Buy |
+37,998
| New | +$129K | 0.01% | 736 |
|
|
2019
Q4 | – | Sell |
-557,477
| Closed | -$1.86M | – | 1060 |
|
|
2019
Q3 | $1.86M | Buy |
557,477
+157,415
| +39% | +$518K | 0.17% | 164 |
|
|
2019
Q2 | $1.32M | Buy |
400,062
+240,280
| +150% | +$695K | 0.12% | 214 |
|
|
2019
Q1 | $484K | Buy |
+159,782
| New | +$518K | 0.05% | 393 |
|
|
2018
Q3 | – | Sell |
-15,676
| Closed | -$40K | – | 985 |
|
|
2018
Q2 | $40K | Buy |
+15,676
| New | +$39K | ﹤0.01% | 714 |
|
|
2018
Q1 | – | Sell |
-12,110
| Closed | -$24K | – | 931 |
|
|
2017
Q4 | $24K | Buy |
+12,110
| New | +$26.4K | ﹤0.01% | 685 |
|
Other funds holding ATRS
Boothbay Fund Management's ATRS Position: Q2 2022 in Review
Boothbay Fund Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 66,276 shares — an estimated $272K sold.
Boothbay Fund Management first reported a position in ATRS in Q4 2017 and held it in 14 quarters. The position peaked at $1.86M in Q3 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Boothbay Fund Management reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Boothbay Fund Management sold 66,276 Antares Pharma, Inc. shares in Q2 2022, an estimated $272K.
- Boothbay Fund Management first reported a position in Antares Pharma, Inc. in Q4 2017 and held it in 14 quarters.
- Boothbay Fund Management's Antares Pharma, Inc. position peaked at $1.86M in Q3 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.